- Home
- DTIL vs XLO Comparison
DTIL vs XLO Comparison
Compare DTIL & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- XLO
- Stock Information
- Founded
- DTIL 2006
- XLO 2016
- Country
- DTIL United States
- XLO United States
- Employees
- DTIL N/A
- XLO N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- XLO Biotechnology: Pharmaceutical Preparations
- Sector
- DTIL Health Care
- XLO Health Care
- Exchange
- DTIL Nasdaq
- XLO Nasdaq
- Market Cap
- DTIL 43.3M
- XLO 36.7M
- IPO Year
- DTIL 2019
- XLO 2021
- Fundamental
- Price
- DTIL $5.55
- XLO $0.84
- Analyst Decision
- DTIL Strong Buy
- XLO Buy
- Analyst Count
- DTIL 3
- XLO 1
- Target Price
- DTIL $37.67
- XLO $4.00
- AVG Volume (30 Days)
- DTIL 196.7K
- XLO 223.3K
- Earning Date
- DTIL 05-12-2025
- XLO 05-13-2025
- Dividend Yield
- DTIL N/A
- XLO N/A
- EPS Growth
- DTIL N/A
- XLO N/A
- EPS
- DTIL 1.04
- XLO N/A
- Revenue
- DTIL $68,696,000.00
- XLO $6,344,000.00
- Revenue This Year
- DTIL N/A
- XLO $668.96
- Revenue Next Year
- DTIL $30.20
- XLO $14.49
- P/E Ratio
- DTIL $5.34
- XLO N/A
- Revenue Growth
- DTIL 40.98
- XLO N/A
- 52 Week Low
- DTIL $3.61
- XLO $0.62
- 52 Week High
- DTIL $13.44
- XLO $1.70
- Technical
- Relative Strength Index (RSI)
- DTIL 59.70
- XLO 59.63
- Support Level
- DTIL $4.90
- XLO $0.71
- Resistance Level
- DTIL $5.75
- XLO $0.86
- Average True Range (ATR)
- DTIL 0.35
- XLO 0.06
- MACD
- DTIL 0.13
- XLO 0.02
- Stochastic Oscillator
- DTIL 88.49
- XLO 90.83
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).